Forgot Password?
Return to Course Listing

CME: Addressing unmet needs and updates in the pharmacotherapeutic management of alpha-1 antitrypsin deficiency (AATD) and its complications

Activity Description / Statement of Need:

In this online, self-learning activity:

Alpha 1-antitrypsin deficiency (AATD), characterized by misfolded and lower function of the serine protease inhibitor alpha-1 antitrypsin (AAT), is a genetic disorder resulting in the degradation of lung structures. Reduced levels of AAT result in overactivity of neutrophil elastase, which destroys connectivetissue within the lung and causes degradation of alveoli, reduced pulmonary elastic recoil, and airflow. Breakdown of the alveoli eventually manifest as chronic obstructive lung disease (COPD), and otherassociated complications include liver disease, which occurs in about ten percent of patients with AATD.The most common cause of death in patients with severe AATD is respiratory failure, which accounts for45 to 72% of deaths.

Target Audience:

The following HCPs: pulmonologists and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in pulmonology and internal medicine; and any other healthcare professionals with an interest in or who clinically encounter patients with AATD.


Commercial Support Disclosure: This program is supported by an educational grant from Grifols.

This activity is free of charge.


Release Date: February 05, 2023 -- Expiration Date: February 05, 2025

Faculty: Alan Barker, MD

Agenda

Faculty introduction, disclosures

Introductory content and review of AATD 

  • Epidemiology
  • Genetic features of AAT and associated phenotypes
  • Lung disease risk factors
  • Clinical presentation: Lung disease, liver disease, other extrapulmonary disease
  • Disease course and complications
  • Healthcare burden

Treatment of AATD

  • The asymptomatic individual: monitoring
  • Goals of care
  • Present and emerging pharmacotherapy
    • Candidates for augmentation therapy
    • Available agents
    • Efficacy and safety
    • Monitoring
    • Practical guidance around augmentation therapy
    • Management of pulmonary, hepatic, and other extrapulmonary complications
    • Investigational therapies
  • Patient cases 

Summary, conclusions, and best practice recap

Learning Objectives

By the end of the session the participant will be able to:

  • Summarize the healthcare burden unique to patients with AATD and challenges to optimal management.
  • Recall the impact of present and emerging pharmacotherapies for AATD and its complications.
  • Formulate a treatment plan for a patient with AATD.

Accreditation

ACCME Activity #202380833

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through ScientiaCME. ScientiaCME is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation: ScientiaCME designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME-MOC_badge

ABIM MOC Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

ABIM MOC Credit Type: Medical Knowledge

Physicians: For maintenance of certification (MOC) points, you must enter your board certification ID # and birth date correctly.  It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive MOC points for this activity. By providing this data, you acknowledge that it will be shared with ACCME and the applicable certifying board. Please note: Not all activities on this site provide MOC points. If this activity does not specify that it provides MOC points in this section, then it does NOT provide MOC points. This activity provides MOC points only for ABIM and ABP.

Pharmacists

ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.1 CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit. ACPE #0574-0000-23-005-H01-P. This is an Knowledge (K)-type activity. 

PharmacistsYou must enter your NABP # and birth date correctly so that proof of participation can be posted to your NABP CPE profile. It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive CPE credit for this activity.

Nurse Practitioners (NPs): The American Academy of Nurse Practitioners accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. ScientiaCME will provide NPs who successfully complete each activity with a certificate of participation indicating that the activity was designated for AMA PRA Category 1 Credit(s)™.


Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved through content review by ScientiaCME.

Disclosure of Faculty: Alan F. Barker, MD, Professor of Medicine, Oregon Health & Science University, has received financial compensation for research from Grifols.

 

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.

Faculty WILL NOT discuss off-label uses.

All relevant financial relationships have been mitigated.

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by an educational grant from Grifols.

Instructions

  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

System Requirements

PC
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
MAC
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version


Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.


Additional Courses That Are Related To This Activity

Optimizing care in advanced non-small cell lung cancer (NSCLC): Zeroing in on personalized medicine with precision

Mesothelioma management Therapeutic updates and best practices

Incorporating biosimilars into practice to treat immunologic disease states: Benefits, concerns, and the present treatment landscape

Opportunities and gaps in the management of chronic hypoparathyroidism